Diabetic Foot Ulcers - Pipeline Review, H1 2018 - Product Image

Diabetic Foot Ulcers - Pipeline Review, H1 2018

  • ID: 4542993
  • Report
  • 138 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ANP Technologies Inc
  • EyeGene Inc
  • GlaxoSmithKline Plc
  • MallInckrodt Plc
  • OliX Pharmaceuticals Inc
  • Serodus ASA
  • MORE
Diabetic Foot Ulcers - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2018, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights:

This latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 9, 2, 15, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ANP Technologies Inc
  • EyeGene Inc
  • GlaxoSmithKline Plc
  • MallInckrodt Plc
  • OliX Pharmaceuticals Inc
  • Serodus ASA
  • MORE
Introduction

Diabetic Foot Ulcers - Overview

Diabetic Foot Ulcers - Therapeutics Development

Diabetic Foot Ulcers - Therapeutics Assessment

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development

Diabetic Foot Ulcers - Drug Profiles

Diabetic Foot Ulcers - Dormant Projects

Diabetic Foot Ulcers - Discontinued Products

Diabetic Foot Ulcers - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Boston Therapeutics Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2018

Diabetic Foot Ulcers - Pipeline by Energenesis Biomedical Co Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Genentech Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1 2018

Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1 2018

Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2018

Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by MallInckrodt Plc, H1 2018

Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by OliX Pharmaceuticals Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1 2018

Diabetic Foot Ulcers - Pipeline by ProMetic Life Sciences Inc, H1 2018

Diabetic Foot Ulcers - Pipeline by Serodus ASA, H1 2018

Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2018

Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H1 2018

Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H1 2018

Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H1 2018

Diabetic Foot Ulcers - Dormant Projects, H1 2018

Diabetic Foot Ulcers - Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Foot Ulcers - Dormant Projects, H1 2018 (Contd..2), H1 2018

Diabetic Foot Ulcers - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ANP Technologies Inc
  • Boston Therapeutics Inc
  • CardioVascular BioTherapeutics Inc
  • Chrysalis BioTherapeutics Inc
  • CytoTools AG
  • Energenesis Biomedical Co Ltd
  • EyeGene Inc
  • FirstString Research Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Human Stem Cells Institute
  • Izun Pharmaceuticals Corp
  • Lakewood-Amedex Inc
  • MallInckrodt Plc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • OliX Pharmaceuticals Inc
  • Oneness Biotech Co Ltd
  • Pherecydes Pharma SA
  • ProMetic Life Sciences Inc
  • Serodus ASA
  • Stempeutics Research Pvt Ltd
  • TechnoPhage SA
  • Topadur Pharma AG
  • USV Pvt Ltd
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll